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Cystic fibrosis (CF) is an autosomal genetic disease that causes infection in the lungs due 
to a lack of mucus clearance in the airways. Published studies on fungal pathogens in CF patients 
noted that the use of multiple antibiotics to treat drug-resistant bacterial infections in these 
patients has created an opening for colonization of the lung with fungal pathogens, and these 
organisms may also be drug-resistant. I hypothesized that fungal pathogens can be isolated 
from CF patient samples, and these fungal organisms will be resistant to antifungal 
therapies. Sputum samples were taken from CF patients from the Cystic Fibrosis Clinic in 
Oklahoma City, OK. Samples were plated using selective media to enrich for fungal growth.  
Following this, single colonies were isolated and cultured for inoculation of biochemical tests 
(API AUX20 C test strips) or for isolation of DNA. DNA samples were subjected to PCR for the 
ITS3 gene followed by gel electrophoresis to identify fungal ITS3 bands. Isolates with positive 
ITS3 bands were sequenced to identify the fungal species. In addition, MIC assays were 
conducted with antifungal drugs. Analysis of colonies tested by API test strips showed that 
several Candida species were present, and we further confirmed the species by sequencing the 
ITS3 gene. MIC assays were conducted with antifungal drugs fluconazole, caspofungin, and 
novel compound EIPE-1. MIC assays showed that some of these isolates were resistant to typical 
antifungal drugs and all were sensitive to EIPE-1. Further understanding the fungal pathogens 
and drug resistance in CF patients as well as identifying alternatives to current antifungal drugs 





Cystic Fibrosis is a common, autosomal recessive genetic disease that results in infection 
in the lungs due to a lack of mucus clearance in the airways [1]. A key feature of CF is the 
imbalance of salt and water within the cell that results from a mutation in the cystic fibrosis 
transmembrane conductance regulator gene (CFTR) [2]. When this gene is disrupted, chloride 
becomes trapped inside the cells causing cell dehydration and mucus build up. Complications arise 
when the CFTR gene is mutated meaning the overall function of the body’s cells, tissues, organs, 
and sweat glands are negatively affected [3].  
In healthy individuals, the CFTR gene is responsible for making the CF transmembrane 
conductance regulator protein [3]. Production of the CFTR protein begins in the cell’s nucleus, 
where the CFTR gene gives instructions responsible for making the protein [2]. Transcription then 
occurs, and RNA matches these instructions in the DNA. Ribosomes take these instructions from 
RNA and translate them to make the CFTR protein. After translation, trafficking allows the CFTR 
protein to move from the cell to the cell’s surface where it acts as a channel in the lungs. From 
there, chloride ions are transported across the cell membrane from inside the cell to the outside. 
When the chloride ions reach the outside of the cell, they attract water which then allows for cilia 
to move mucus through the airways. However, if the CFTR gene is mutated then complications 
with the CFTR protein will arise, and chloride ions will become trapped inside the cell causing 
thick, viscous mucus to build up and flatten the cilia [2]. Since water is no longer being attracted 
to the chloride ions and the cilia are flattened, the mucus cannot be swept out of the airways 
ultimately leading to pathogen colonization and respiratory related complications [4]. Mucus is 
necessary for lining multiple organs including those of the respiratory tracts, pancreas, intestines, 
and sweat glands; however, because individuals with CF have thicker mucus and are more prone 
to blockage, then organ issues or failure is inevitable.  
Approximately 2000 mutations have been discovered that are associated with CF [5]. 
Deletions or alterations in the protein’s amino acid sequence are the most common mutations of 
the CFTR protein and effect the chloride channel’s production, structure, and stability. Other 
mutations tend to have different effects on the protein; meaning, on a molecular level the variation 
of CFTR mutations has the ability to impact patient symptoms along with the organs that are 
affected which can alter patient treatments [5]. In terms of who is at risk for CF, the disease is most 
common within Caucasian and northern European populations occurring for every 1 in 3,200 births 
[6]. For African Americans, CF occurs at around 1 in 15,000 births, and is relatively uncommon 
among Asian, Native American, and Hispanic populations. 
 
CFTR FUNCTION 
The CFTR protein channel operation is powered by ATP regulation and phosphorylation 
of the R domain via cAMP-dependent protein kinase [7]. CFTR has been classified as an ATP-
binding cassette protein making it a member of the ABC protein subfamily. The CFTR protein’s 
ATP-gated ion channel is unique in that it transports chloride ions via passive diffusion whereas 
other proteins of this family would normally use free energy of ATP hydrolysis to export anions 
[8]. Essentially, CFTR is not like other classical ligand-gated ion channels; instead, channel 
opening and closing is dependent on the uptake of ATP during its gating cycle. The channels open 
when ATP binds to the ATP binding site on the nucleotide binding domains and they close when 
ATP is consumed. Since CFTR is found primarily in mucosal and secretory epithelia, the overall 
transportation of negatively charged chloride ions through this channel is necessary for water 
movement in tissues and normal mucus production [8]. 
 
DIAGNOSIS 
 The genetic nature of cystic fibrosis implies that patients may be diagnosed through 
medical history as well as genetic and molecular testing [6]. Since CF is genetic, gathering medical 
history along with the patient’s family history is helpful for physicians before conducting genetic 
testing in the laboratory. The goal of genetic testing for CF is to detect any mutations within the 
CFTR genes, the most common mutation being DF508 [9]. However, there are over 1,500 CFTR 
mutations and genetic testing screens for only a limited portion of these mutations.  Prenatal testing 
involves the same concept through procedures called amniocentesis and chorionic villus sampling 
(CVS) where amniotic fluid or tissue from the placenta is taken from the mother and the cells are 
tested for CFTR mutations [6]. If the unborn child tests positive for a CFTR mutation, then further 
genetic testing will occur after birth. Meanwhile, the most common and standard testing procedure 
for CF is a sweat test because of abnormally high levels of sodium and chloride in the sweat caused 
by the mutations in the CFTR. Sweat tests involve increasing sweat production through chemical 
and electrical stimulation to the arm or leg where sweat is collected and sent off for analysis of 
chloride concentrations [9]. Chloride levels of greater than or equal to 60 millimoles per Liter are 
indicative of CF. Levels less than 30 millimoles per Liter suggest that having CF is either unlikely, 
or the patient is atypical of CF symptoms meaning they may not express all classical CF 
phenotypes [9].    
 
 
SYMPTOMS AND PHENOTYPES 
Symptoms of cystic fibrosis vary among individuals depending on the severity of the 
disease, CFTR mutation, and organ sensitivity [5]. The most common organs affected are those 
within the pulmonary and respiratory tract, primarily the lungs, but organs such as the pancreas, 
liver, intestines, and reproductive organs are also affected. Mucus buildup in the lung’s airways 
allows bacteria and fungi to colonize and cause ongoing infections such as allergic 
bronchopulmonary aspergillosis, an allergic reaction that occurs in the lungs from the fungus 
Aspergillus [10]. Bronchiectasis is also very common in CF and results from airway obstruction 
and chronic inflammation of the lungs. The gastrointestinal system is the next most affected organ 
system in CF patients, primarily the pancreas. Inside the pancreas, thick mucus is created by 
mutated exocrine glands and inhibits digestive enzymes from traveling to the small intestine via 
pancreatic ducts. This inhibition causes digestion and nutrient absorption complications causing 
diabetes, malnutrition, pancreatitis, abdominal pain, etc. [5, 6] . Other symptoms involve intestinal 
blockage at birth, abdominal pain, jaundice, low body mass index, muscle and joint pain, delayed 
growth, infertility, salty skin, salty sweat, sinus infections, heart failure, and liver disease. In 
addition to genetic mutation, CF symptoms are also subject to several environmental cursors 
including air pollution, climate, humidity, temperature, dust, second-hand smoke, socioeconomic 
status, and geographical location [11]. Studies have shown that the rise in air pollution has 
increased the risk of pulmonary exacerbations in CF patients, and exposure to secondhand smoke 
can negatively impact mucus clearance and respiratory therapy [12]. Current and future research 
on the environmental impact on CF patients is beneficial and necessary in understanding CF 
pathophysiology as well as how quality of life can be improved.   
 
PATHOGENESIS 
Airway obstruction and chronic inflammation of the lungs from CF allows bacterial 
pathogens to occupy lung pathways [10]. Since CF patients are already immune deficient and lack 
cilia to clear mucus, this makes bacterial infections difficult to treat especially if not treated early 
on. While the primary pathogens of CF are Staphylococcus aureus and Pseudomonas aeruginosa, 
different stages of CF involve different pathogens [10]. Namely, Hemophilus influenza and S. 
aureus tend to cause infection in the first decade of life. During the second and third decades, P. 
aeruginosa becomes the main pathogen of the lung where it has the ability to form biofilms, 
ultimately prolonging infection in the lungs and resisting antibiotic treatment. Previous studies 
have shown that the lungs of CF patients can also harbor fungal pathogens where treatment of 
fungal infections can lead to drug-resistance [13]. It is also becoming increasingly recognized that 
fungal biofilms can persist in the lung and contribute to pathology and are highly resistant to 
antifungal therapy [10]. Further understanding the composition and drug resistance of bacterial 
and fungal pathogens in CF patients could potentially prolong CF patient lifespan and decrease the 
severity of their lung infections.  
 
TREATMENT 
 When treating CF, addressing the condition of the lungs is usually the first step before 
infection can increase or worsen since lung disease usually occurs before other symptoms [6]. 
Clearing the airways of mucus build up, fighting bacterial or fungal infections through 
antimicrobial drugs, or even surgery are all techniques used to treat CF patients. In order to clear 
lung airways, airway clearance techniques (ACTs) is a common and chronic treatment among CF 
patients that loosens mucus through coughing in order to reduce blockage, decrease infections, and 
improve overall respiratory function. Medications are also prescribed to CF patients to be used in 
combination with ACTs including antibiotics, anti-inflammatory drugs, bronchodilators, mucus 
thinners, and CFTR modulators [6]. Surgery may be necessary in worse cases leading to lung or 
liver transplants.     
In the last 70 years, treatment and diagnosis of cystic fibrosis has evolved drastically due 
to highly progressive CF research [14]. During the 1940s, CF antibiotic therapy began with 
penicillin to help with chronic coughing and transitioned into using intravenous drugs such as 
gentamicin and tobramycin in the 1980s. The early 2000s focused on using azithromycin, a pill 
taken orally about 3 times a week to help combat chronic bacterial infections and improve lung 
function [6, 14]. Advancements in drug development have also led to high resolution imaging that 
has allowed researchers to recognize where and how drugs bind to the CFTR protein giving insight 
on potential therapies. However, imaging is still limited, and the protein is still unable to be shown 
in an open position that would further display how chloride ions moves through the ion channel 
[2]. Proper diet and nutrition is also crucial for nutrient absorption and weight gain for those with 
pancreatic and gastrointestinal complications. CF diets are normally high in calories, fat, protein, 
and salt to help immunity and muscle growth; nutritional supplements like pancreatic enzymes and 
vitamins are also essential for digestion and absorption [6]. 
 
FUNGAL-BACTERIAL INTERACTIONS 
Fungi are eukaryotic organisms that exist in unicellular or multicellular form in a variety 
of environments [15]. Unlike bacteria, fungi differ in structure in that fungal cell walls are 
comprised of cross-linked glucans  and contain ergosterol in the membrane, whereas peptidoglycan 
is the main component in bacterial cell walls [16]. These structural differences are clinically 
relevant since antibacterial and antifungal agents are designed to target these different cell wall 
components. As previously mentioned, respiratory secretions from cystic fibrosis patients are 
home to certain filamentous fungi and yeasts [17]. Of these, Candida albicans is one of the most 
predominant fungal pathogens isolated from CF sputum [17].  
 Over 200 Candida species have been identified, however, only a few are considered 
opportunistic pathogens including Candida albicans [18]. Candida albicans is a normal resident 
of the human microbiota found on the skin and within the gastrointestinal tract and genital tract 
[19, 20]. In hosts, C. albicans can exist as a yeast or in a filamentous form known as hyphae [21]. 
Though Candida albicans is a normal commensal in humans, colonization is greatly increased in 
immunocompromised individuals which can then involve other bacterial or fungal opportunists 
[22]. Since the airways of Cystic Fibrosis are lined with an abnormal layer of viscous mucus, this 
enables the formation of biofilms, polymicrobial infections, and inter-kingdom interactions [10]. 
One of the most common yet controversial inter-kingdom relationships of the CF lung involves 
the interaction between Pseudomonas aeruginosa and Candia albicans. The controversy of this 
interactions stems from the fact that it can be either synergistic or antagonistic. It has been shown 
that P. aeruginosa can induce biofilm formation on filamentous hyphae of C. albicans causing 
death [19]. The exception to this is that P. aeruginosa does not bind to C. albicans in its yeast form 
likely due to differences in yeast and hyphae cell walls thus causing selective attachment. This 
fungicidal activity allows P. aeruginosa to occupy more surface area within the CF lung and obtain 
nutrients from the fungal filaments, ultimately representing the antagonistic nature of this inter-
kingdom interaction [20]. Other in vivo murine studies of with P. aeruginosa and C. albicans have 
suggested that prior colonization of Candida may reduce overall P. aeruginosa infection and CF 
lung injury [23]. Alternatively, C. albicans produces the quorum sensing molecule farnesol which 
allows the pathogen to inhibit germ tube formation and remain in its yeast form, a defense 
mechanism against P. aeruginosa [24]. Farnesol also prevents P. aeruginosa from producing 
pyocyanin, a virulence factor toxic to eukaryotic cells, which inhibits the morphology transition 
of C. albicans from yeast to hyphae and preventing fungal biofilm formation in the lungs [24]. 
 While Candida albicans has undoubtedly been recognized as a predominant fungal 
pathogen in the CF lung, it has also been questioned whether C. albicans colonization is a true 
reflection of CF fungal pathogenesis or is simply a contamination [10, 17]. Essentially, this clinical 
uncertainty suggests that sputum samples may be contaminated via the environment, laboratory 
processing, or through colonization of existing commensal yeasts. In retrospect, sputum samples 
that test positive for C. albicans or any fungal agent may lead to unnecessary antifungal therapy 
thus resulting in drug resistance [25].  
 
ANTIFUNGAL AGENTS & RESISTANCE  
 Fungal infections in Cystic Fibrosis lungs are often difficult to treat due to the close 
evolutionary relationship between eukaryotic cells and human cells [26]. More obviously, because 
antifungal drugs are toxic to fungal organisms, they are also toxic to human hosts. There has also 
been a rapid increase in fungal infections and development of antifungal drug resistance limiting 
effective treatment strategies [26].  
Based on their mechanism of action, antifungal agents are grouped into three classes: azoles, 
polyenes, and echinocandins. Azoles are involved in the biosynthesis of ergosterol, a component 
necessary for maintaining the integrity of the fungal cell wall [27]. Polyenes bind to ergosterol and 
form pores in the membrane releasing molecules necessary for ion balance and membrane integrity 
[26]. Finally, echinocandins are the most recent of the antifungal drug classes and target the 
enzyme beta-(1,3)-D-glucan synthase which is needed to synthesize cell wall component beta-
(1,3)-D-glucan [15]. For this particular study, antifungal agents fluconazole (azole), caspofungin 
(echinocandin), and novel antimicrobial EIPE-1 were used to treat and evaluate the drug 
susceptibility of fungal organisms in CF sputum. The Clinical and Laboratory Standards Institute 
(CLSI) classifies the resistance breakpoints of Candida albicans and Candida dubliensis as ³8 
µg/mL for fluconazole and ³1 µg/mL for caspofungin [28, 29]. For Candida lusitaniae, MICs 
range from 0.125-8 µg/mL for fluconazole and 0.03-1 µg/mL for caspofungin [29].  EIPE-1 is a 
eumelanin derived antimicrobial compound developed by Dr. Toby Nelson in the Department of 
Chemistry at Oklahoma State University [30]. Eumelanin belongs to a class of biomacromolecular 
pigments called melanins that are protective against UV light and contribute to hair, skin, and eye 
color in humans and animals. Microorganisms have the ability to produce eumelanin as a defense 
mechanism in hosts, a concept that is clinically relevant since the success of some 
antimicrobial drugs is dependent on host defenses [30]. 
 
MATERIALS & METHODS 
 
Sample isolation: Approximately 24 sputum samples from de-identified CF patients from the 
Oklahoma City Cystic Fibrosis Clinic were collected and the clinical samples were frozen at -80 
in skim milk.	After thawing the frozen clinical samples, they were struck onto a selective media 
consisting of skim milk agar with the antibiotic chloramphenicol and were incubated for two days 
at 30° C. Isolated colonies were then subcultured onto additional skim milk agar. Skim milk agar 
promotes fungal growth and inhibits bacterial growth due to its low pH, and the addition of 
chloramphenicol is a preventative measure for contamination due to bacteria within the samples.  
Microscopy: Each sample was viewed microscopically to initiate fungal isolation. Samples that 
displayed yeast or filamentous morphology were selected for further study. To prevent 
contamination, samples with similar morphology to Aspergillus species were eliminated from the 
experiment. 
DNA purification: Single fungal colonies were isolated and purified using a fungal DNA isolation 
kit from Zymo Research according to manufacturer’s instructions. DNA concentration and purity 
were determined using the Synergy HTX multimode reader (BioTek) using a Take 3 microvolume 
plate.		
ITS3	PCR:	After completing purification, ITS3 PCR was performed. The PCR mixture contained 
12.5µL Thermo Scientific DreamTaq Mastermix, 1µL forward primer, 1µL reverse primer, 0.5 µL 
DNA template, and 10 µL nuclease-free H2O for a total of 25µL of reaction mixture. The 
denaturation step was programmed at 95°C for 1 minute, the annealing step was programmed at 
52°C for 30 seconds, and the extension step was programmed at 72°C for 1 minute and 30 seconds. 
The total reaction consisted of 30 cycles, and the final extension was programmed at 72°C for 5 
minutes.  
DNA electrophoresis: After PCR was completed, DNA gel electrophoresis was performed to 
identify fungal bands with a size of 500 bp. An 8% agarose gel was prepared, and samples were 
run at 100 volts for one hour. The gel was then imaged on the Bio-Rad Gel Documentation System 
in order to view any potential fungal bands.   
Fungal identification using API test strips and DNA sequencing: API AUX20 C biochemical 
test strips (BioMerieux) containing 20 biochemical tests were inoculated with each fungal isolate 
and incubated for 48-72 hours according to manufacturer’s instructions. Identification was based 
off a 7-digit numerical profile by adding the numbers corresponding to the positive reactions. Each 
7-digit profile was entered into the apiweb identification database.  
MIC assays: Fungal growth inhibition was measured by performing Minimum Inhibitory 
Concentration (MIC) assays for each fungal patient sample CLSI guidelines [CLSI, 2008]. with 
the antifungal drugs Fluconazole, Caspofungin, and novel drug EIPE-1. On a 96 well plate, 200 µl 
of each drug was added into row 12 and diluted by 100 µl down each row beginning at row 12 and 
ending at row 2 where row 1 served as the control and contained no drug. After dilution, 100 µl of 
fungal samples was added to the entire plate. Each plate was incubated for 48 hours at 35°C and 
then placed onto a plate reader to measure optical density. The last “clear” row without fungal 
growth was considered the MIC concentration. 
 
RESULTS 
Fungal colonies were identified from cystic fibrosis patient samples. For these studies, 24 
patient samples were thawed and streaked onto skim milk agar plates in order to determine the 
presence of fungal organisms in the patient samples. After 48 hours, colonies were analyzed by 
microscopy for size (>5 um in diameter) and morphology (yeast or hyphae). Colonies that met 
these criteria were presumed to be fungi and were subjected to additional assays. We found 8 
fungal isolates from the 24 patient samples, and 0 patients had multiple fungal colonies present 





     
Bacteria 
32014B 31314A 8714C 21314A 22714D 102314A 102314H 112014B 
102314O 11614D 11614E 112014A 8714C 81414C 9414D 112014C 
Fungi 31614A 2515A 8414D 8714E     
Both 22014C 22714E 21314B 22714A     
 
Table 1. Patient samples were separated according to microbial species found. A total of 16 samples contained 
bacteria only, 4 samples contained only fungi, and 4 samples contained both bacterial and fungal species 
 
PCR for ITS3 revealed the presence of fungal organisms from CF clinical samples. In order 
to confirm that fungal species were present in our clinical samples, DNA was isolated from each 
isolate, followed by PCR for ITS3. Those with bands corresponding to the size of the ITS3 gene 
(500 kb) were then sequenced.  Out of 24 total samples subjected to ITS3 PCR, gel electrophoresis 
revealed that 8 of these samples contained bands corresponding to the size of the ITS3 gene (Figure 
1). Sample 11614D displayed a false positive for band imaging due to environmental 















Figure 1. DNA gel showing bands after ITS3 PCR amplification. Following PCR amplification of the ITS3 
gene, samples were run on an agarose gel at 100 volts for one hour. The gel was then imaged on the Bio-Rad 
Gel Documentation System. Lanes 1-5 show potential ITS3 bands. 
 
ITS3 sequencing and API biochemical tests identified the fungal species from CF clinical 
samples. Following positive ITS3 bands (Figure 1), these fungal isolates were identified to the 
genus and species level by API test strips and by DNA sequencing of the ITS3 gene. Using the 
API database, patient samples 22714A and 22014C were identified as Candida famata, and 
22714E, 21314B, and 31614A as Candida albicans (Table 2). However, sequencing results 
identified patient samples 22714E and 21314B as Candida albicans, 22714A and 31614A as 





Fungal isolates from the CF clinical samples were resistant to antifungal drugs but sensitive 
to a novel antimicrobial compound. Minimum inhibitory concentration (MIC) assays were 
conducted using fluconazole, caspofungin, and a novel antimicrobial compound, EIPE-1. Results 
showed resistance to fluconazole in patient 22014C (Candida lusitaniae) (Table 3 and Figure 2). 
Patient sample 21314B showed resistance to caspofungin (Table 3 and Figure 3). No resistance 
was shown against novel, eumelanin derived drug EIPE-1 (Table 3 and Figure 4), suggesting 
Patient ID API Test DNA Sequencing  
22714A Candida famata Candida dubliensis 
22714E Candida albicans Candida albicans 
22014C Candida famata Candida lusitaniae 
21314B Candida albicans Candida albicans 
31614A Candida albicans  Candida dubliensis 
Table 2. Identification of fungal species using API database and ITS3 DNA Sequencing 
 
potential use for Candida infections. The wild-type C. albicans species SC5314 was used as a 
control.  
 
 Minimum Inhibitory Concentrations: MIC (µg/ml) ± SEM 
 22714E 22714A 21314B 22014C 31614A SC5314 
Fluconazole  0.3268±0.227 0.2943±0.09636 34.11±32.94 0.3418±0.2238 0.3581±0.2135 0.3255±0.0651 
Caspofungin 0.2461±0.1445 0.2461±0.1445 12.70±12.30  6.445±6.055 0.3906±0.0 








 Figure 2. Fluconazole MIC for clinical samples. Samples were tested to determine the MIC of each isolate to 
fluconazole. Data shown are means  +/- SEM from 2-3 experiments with each clinical isolate.  
Table 3. Minimum inhibitory concentrations for clinical samples and antifungal agents fluconazole, caspofungin, and 









Figure 3. Caspofungin MIC for clinical samples. Samples were tested to determine the MIC of each isolate to 
caspofungin. Data shown are means  +/- SEM from 2-3 experiments with each clinical isolate.   
Figure 4. EIPE-1 MIC for clinical samples. Samples were tested to determine the MIC of each isolate to EIPE-
1. Data shown are means  +/- SEM from 2-3 experiments with each clinical isolate.  
CONCLUSION 
There is growing concern regarding fungal pathogen colonization within Cystic Fibrosis 
lungs. Not only do fungal pathogens like Candida albicans prolong microbial infections they 
also give rise to rapid drug resistance [10]. In terms of treatments and drug development, high 
resolution imaging has offered insight on the pharmacodynamics between drugs and the CFTR 
protein, however, imaging limitations prevent the view of CFTR protein channel operations [2]. 
Inter-kingdom interactions between fungal and bacterial species have shown great controversy in 
CF airways due to antagonistic behaviors. Though P. aeruginosa biofilms enable the destruction 
and killing of Candida hyphae, the bacterial pathogen is able to obtain nutrients and survive in 
the lung [19]. Alternatively, C. albican’s production of farnesol inhibits growth of P. aeruginosa 
allowing for its own survival. Ongoing polymicrobial infections prolong administration of 
antimicrobial agents in Cystic Fibrosis patients imposing risk of organisms becoming multi-drug 
resistant. In turn, increased levels of drug resistance make it harder for researchers to develop 
novel antifungal drugs. 
 The initial hypothesis of this study aimed for identification of fungal pathogens in CF 
patient sputum samples, and that these fungal organisms would show resistance to antifungal 
therapies.  However, the results indicate that only some resistance was shown against antifungal 
drugs fluconazole and caspofungin, while multiple Candida species showed consistent 
sensitivity towards the novel, eumelanin derived antimicrobial EIPE-1 indicating its potential use 
for antifungal therapies. Although CF still has no cure, the overall improvement of CF patient 
quality of life is the first step. Effective combination therapy that addresses both CFTR function 
and pathogenesis of the lungs along with development of enhanced diagnostic tools is imperative 
and necessary. Understanding the drug resistance behind bacterial and fungal interactions within 
the lungs would allow for producing better antimicrobial drugs that inhibit both pathogens from 
colonizing and increasing CF infections. Further CF research, clinical trials, and in vivo studies is 
crucial for expansion of other combination therapies, especially those that can be used to treat 
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